dr. richardson on isatuximab triplet regimen in relapsed/refractory myeloma
Published 5 years ago • 229 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:51
dr. richardson on the fda approval of isatuximab in relapsed/refractory myeloma
-
5:03
paul richardson: isatuximab improves pfs in relapsed/refractory myeloma
-
2:09
dr. richardson on results of the horizon trial in relapsed/refractory multiple myeloma
-
1:32
dr. richardson on immunotherapy advances in relapsed/refractory myeloma
-
1:35
comparing results for 3-drug and 2-drug regimens in relapsed/refractory myeloma
-
6:46
choosing triplet therapy at myeloma relapse
-
1:20
dr. yee on the utility of isatuximab in combination therapy for relapsed/refractory myeloma
-
1:36
dr. richter on the utility of isatuximab in relapsed/refractory myeloma
-
5:11
asco 2019: isatuximab icaria-mm trial updates with dr. paul richardson
-
1:00
dr. richardson on the next steps with cc-92480 research in relapsed/refractory multiple myeloma
-
2:04
pomalidomide-based triplets improve responses in relapsed/refractory multiple myeloma
-
8:36
relapsed/refractory myeloma: daratumumab-containing triplets
-
4:30
triplet regimens for relapsed multiple myeloma
-
1:16
triplet regimens with pomalidomide in patients with multiple myeloma
-
1:16
dr. costello on the future of isatuximab in relapsed/refractory multiple myeloma
-
7:23
management of relapsed/refractory multiple myeloma
-
2:41
isatuximab: a ‘next-generation monoclonal antibody’
-
2:20
icaria: isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
-
2:32
paul g. richardson, md, considers progression-free survival in mm when treating with isatuximab